Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells 22,355 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 22,355 shares of Invivyd stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $16,095.60. Following the completion of the transaction, the insider directly owned 197,362 shares of the company’s stock, valued at approximately $142,100.64. This represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Timothy Edward Lee also recently made the following trade(s):

• On Tuesday, August 18th, Timothy Edward Lee sold 18,425 shares of Invivyd stock. The stock was sold at an average price of $0.84, for a total transaction of $15,477.00.

Invivyd Stock Performance

Shares of IVVD traded up $0.13 during mid-day trading on Tuesday, hitting $0.87. 7,732,095 shares of the company’s stock were exchanged, compared to its average volume of 3,061,089. The stock’s 50-day moving average is $0.77 and its 200-day moving average is $1.23. Invivyd, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $3.07. The company has a market cap of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The business had revenue of $14.29 million during the quarter, compared to analyst estimates of $14.40 million. As a group, equities research analysts anticipate that Invivyd, Inc. will post -0.52 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on IVVD shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. BTIG Research reiterated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. HC Wainwright reissued a “buy” rating on shares of Invivyd in a research note on Tuesday. Finally, Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Invivyd currently has an average rating of “Hold” and an average target price of $8.00.

Key Invivyd News

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Jupiter Topco LLC purchased a new stake in shares of Invivyd in the 2nd quarter valued at approximately $30,048,000. Janus Henderson Group PLC lifted its position in shares of Invivyd by 1.7% during the 1st quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company’s stock worth $42,857,000 after purchasing an additional 551,188 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in shares of Invivyd during the 4th quarter worth $53,809,000. BVF Inc. IL acquired a new position in shares of Invivyd during the fourth quarter worth $48,227,000. Finally, RA Capital Management L.P. acquired a new position in shares of Invivyd during the third quarter worth $18,831,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.